FDA Section 506J Medical Device Shortage Reporting: Mandatory Notification, the 506J Device List, and Supply Chain Resilience

Why Medical Device Shortage Reporting Matters

Medical device shortages are not theoretical risks. They are recurring events with direct consequences for patient care. When a manufacturer permanently discontinues a neurosurgical patty, an oxygenator, or a hemodialysis bloodline, hospitals lose access to devices they depend on for surgery, cardiac bypass, and life-sustaining treatment. The downstream effects cascade through procurement teams, clinical staff, alternative device evaluations, and ultimately patient outcomes.

The COVID-19 pandemic made this reality unavoidable. From ventilators and pulse oximeters to surgical gloves and diagnostic test kits, supply chain failures affected virtually every category of medical devices. In many cases, the FDA learned about disruptions only after shortages had already materialized -- too late for the agency to coordinate mitigations, identify alternatives, or prioritize its own regulatory flexibilities.

Section 506J of the Federal Food, Drug, and Cosmetic Act was created to address this gap. Enacted as part of the CARES Act on March 27, 2020, Section 506J requires device manufacturers to notify the FDA of permanent discontinuances or interruptions in manufacturing that could lead to a meaningful disruption in the domestic supply of critical devices. The goal is straightforward: give the FDA early warning so it can act before a shortage harms patients.

This guide covers everything regulatory affairs and quality professionals need to know about Section 506J -- the legal framework, the notification requirements, the 506J Device List, the FDA's Office of Supply Chain Resilience, current shortages, and the practical steps your organization should take to comply and prepare for changes ahead.

The Legal Framework: Section 506J of the FD&C Act

Statutory Authority and Scope

Section 506J was added to the FD&C Act by Section 3111 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into law on March 27, 2020. It grants the FDA authority to require device manufacturers to report certain supply chain disruptions during, or in advance of, a public health emergency.

The statute applies to manufacturers of devices that are "critical to public health" or for which the FDA has determined that notification is necessary. The definition of "manufacturer" under Section 506J is broad and includes any entity that manufactures, prepares, propagates, compounds, assembles, or processes a device -- capturing domestic manufacturers, foreign manufacturers whose devices enter US commerce, specification developers, and repackagers/relabelers.

Key Definitions

Section 506J establishes several important definitions that shape reporting obligations:

"Shortage" is defined under Section 506J(j)(2) as "a period of time when the demand or projected demand for the device within the United States exceeds the supply of the device." This is a forward-looking definition -- it encompasses not only existing shortages but also projected demand exceeding supply, which means manufacturers must evaluate their pipeline and forecast data, not just current inventory levels.

"Permanent discontinuance" means the manufacturer has decided to cease production of the device entirely. This includes situations where a company exits a product line, retires a device model, or discontinues manufacturing at a specific facility without transferring production elsewhere.

"Interruption in manufacturing" means a significant slowdown or temporary halt in production that is not a permanent discontinuance. This covers raw material shortages, manufacturing line failures, quality issues requiring production holds, staffing disruptions, facility damage, regulatory compliance issues, and supply chain bottlenecks affecting key components.

"Meaningful disruption in supply" is the threshold that triggers the reporting obligation. The manufacturer must assess whether the discontinuance or interruption is likely to lead to a meaningful disruption in the domestic supply of the device. This requires a good-faith evaluation of the device's market share, the availability of alternatives, the clinical significance of the device, and the duration of the expected disruption.

When Notification Is Required

Under Section 506J(a), a manufacturer must notify the FDA during, or in advance of, a public health emergency when the manufacturer:

1. Permanently discontinues the manufacture of a device that is critical to public health
2. Interrupts the manufacture of a device that is critical to public health, and the interruption is likely to lead to a meaningful disruption in supply

The notification must be provided "as soon as practicable" but no later than the date on which the discontinuance or interruption occurs. The FDA expects manufacturers to err on the side of early notification -- waiting until a shortage materializes defeats the purpose of the statute.

The 506J Device List

What Is the 506J Device List

The FDA maintains a specific list of product codes for which manufacturers are required to notify the agency under Section 506J. This is commonly referred to as the "506J Device List." Manufacturers of devices whose product codes appear on this list have a mandatory obligation to report permanent discontinuances or manufacturing interruptions during, or in advance of, a public health emergency.

The list is not static. The FDA updates it periodically as new product codes are identified as critical to public health or as new shortage risks emerge. Manufacturers should check the list regularly and subscribe to FDA communications to stay current on additions.

How the List Affects Your Reporting Obligations

The 506J Device List creates a clear dividing line between mandatory and encouraged reporting:

This distinction is central to understanding your obligations. If your device is on the list, failure to notify the FDA during a public health emergency is a violation of federal law. If your device is not on the list, notification is voluntary -- but the FDA strongly encourages all manufacturers to report disruptions regardless of list status, because the agency's ability to prevent and mitigate shortages depends on having timely information.

Why Voluntary Reporting Matters

The FDA has been explicit that it relies on voluntary notifications to supplement the mandatory framework. Many significant shortages in recent years involved devices that were not on the 506J Device List at the time. Voluntary reports from manufacturers, healthcare providers, distributors, and group purchasing organizations (GPOs) have been instrumental in helping the FDA identify and address emerging supply chain risks.

Anyone -- not just manufacturers -- can report a device shortage to the FDA by emailing deviceshortages@fda.hhs.gov. The FDA encourages healthcare providers, patients, distributors, and GPOs to use this channel to report shortages they encounter in clinical practice or the supply chain.

The Office of Supply Chain Resilience (OSCR)

Organization and Mission

Within the FDA's Center for Devices and Radiological Health (CDRH), the Office of Supply Chain Resilience (OSCR) is the organizational unit responsible for anticipating and preventing disruptions to supply chains for medical devices. OSCR sits within the Office of Strategic Partnerships and Technology Innovation (OST), reflecting the FDA's view that supply chain resilience is fundamentally a collaborative endeavor that requires engagement with industry, healthcare providers, and other government agencies.

OSCR's mission extends beyond simply tracking shortages. The office works to:

• Anticipate supply chain disruptions before they materialize, using data from mandatory notifications, voluntary reports, market intelligence, and international regulatory partners
• Prevent shortages by coordinating with manufacturers on mitigation strategies, facilitating temporary regulatory flexibilities where appropriate, and connecting stakeholders with alternative supply sources
• Manage active shortages by maintaining the Medical Device Shortage List, communicating with the healthcare community, and monitoring resolution progress
• Strengthen long-term supply chain resilience through policy development, stakeholder engagement, and legislative advocacy

OSCR Organizational Structure

OSCR comprises two divisions, each with distinct but complementary responsibilities:

Division of Prevention, Innovation and Resilience -- focused on proactive supply chain strengthening, including surveillance of supply chain vulnerabilities, development of resilience frameworks, stakeholder engagement, and innovation in supply chain monitoring tools and methodologies.

Division of Shortage Assessment and Product Authentication -- focused on assessing and managing active shortages, maintaining the Medical Device Shortage List and Discontinuance List, evaluating manufacturer notifications, and addressing product authentication concerns that arise during shortage events when counterfeit or diverted products may enter the supply chain.

The Medical Device Shortage List and Discontinuance List

OSCR manages two key lists that are central to the FDA's public communication about device availability:

Medical Device Shortage List (MDSL): This list identifies devices that are currently in shortage -- where demand exceeds supply within the United States. The list includes the product code, device description, the reason for the shortage, and estimated resolution timelines where available. The MDSL is publicly accessible and is updated as new shortages are identified and existing ones are resolved.

Discontinuance List: This list identifies devices that have been permanently discontinued by their manufacturers. As of March 2026, the Discontinuance List contained more than 122 entries spanning a wide range of device categories, including anesthesiology, cardiovascular, clinical chemistry, dental, gastrointestinal/urology, general surgery, general hospital, microbiology, obstetrics/gynecology, orthopedic, and radiology devices. The breadth of this list underscores the scale of device discontinuations in the current market environment and the importance of proactive supply chain monitoring.

Current Device Shortages (as of May 2026)

Active Shortages on the Medical Device Shortage List

The FDA's Medical Device Shortage List includes several device categories with active or ongoing shortages as of May 2026. The following table summarizes the key entries:

Several observations are worth noting:

• Shortages span critical clinical areas. These devices are used in neurosurgery, interventional cardiology, breast cancer diagnosis, cardiac surgery, hemodialysis, and cardiopulmonary bypass. Disruptions in any of these categories directly affect patient care.
• Resolution timelines extend into late 2026. Several of the listed shortages are estimated to persist through Q3 or Q4 2026, meaning hospitals and health systems must plan for extended periods of constrained supply.
• Multiple product codes can be affected simultaneously. The oxygenator shortage affects both BYS and DTZ product codes, indicating a broader supply constraint within the extracorporeal circulation device category.
• Estimated resolution dates are subject to change. The FDA notes that these timelines are manufacturer estimates and may be revised as circumstances evolve.

Discontinuance Trends

The Discontinuance List, with more than 122 entries as of March 2026, reveals patterns that should concern the medical device industry:

• Broad category coverage. Discontinuations are not concentrated in a single specialty. They span anesthesiology, cardiovascular, clinical chemistry, dental, gastrointestinal/urology, general surgery, general hospital, microbiology, obstetrics/gynecology, orthopedic, and radiology -- indicating systemic rather than isolated market exits.
• Cumulative impact on clinical options. Each discontinuation reduces the number of available alternatives for a given device type. When combined with active shortages, the cumulative effect narrows clinicians' choices and increases reliance on remaining suppliers.
• Supply chain concentration risk. When multiple manufacturers exit a product category, the remaining manufacturers gain disproportionate market share -- which creates concentration risk that can amplify the impact of any future disruption affecting those remaining suppliers.

How to Submit a 506J Notification

The FDA 506J Notification Portal

The FDA has established a dedicated portal for submitting Section 506J notifications. The portal is located at:

fdaprod.secure.force.com/shortages/

Manufacturers should familiarize themselves with the portal before a notification is needed. Setting up access, understanding the data fields, and rehearsing the notification process during normal operations will save critical time when an actual disruption occurs.

What to Include in Your Notification

A complete 506J notification should include the following information:

• Device identification -- product code, device name, model/catalog numbers, and any other identifying information
• Manufacturer information -- company name, establishment registration number, contact person
• Nature of the disruption -- whether the event is a permanent discontinuance or a manufacturing interruption
• Reason for the discontinuance or interruption -- the underlying cause (raw material shortage, quality issue, business decision, regulatory action, etc.)
• Expected duration -- for interruptions, the anticipated timeline for resuming production
• Impact assessment -- the manufacturer's evaluation of how the disruption will affect the domestic supply of the device
• Market information -- the device's approximate market share, number of affected patients or procedures, and geographic scope of impact
• Mitigation steps -- any actions the manufacturer is taking to address the disruption, including alternative supply sources, production ramp-up plans, or customer communication strategies

Timing Considerations

The statute requires notification "as soon as practicable" but no later than the date of the discontinuance or interruption. In practice, the FDA expects:

• Advance notification when the manufacturer can foresee a disruption (e.g., a supplier has notified of raw material allocation, a facility shutdown is planned, a regulatory action is anticipated)
• Immediate notification when a disruption occurs without advance warning (e.g., an unexpected equipment failure, a natural disaster, a sudden supplier bankruptcy)
• Updated notifications when circumstances change -- if the expected duration extends, if the impact assessment changes, or if the disruption resolves earlier than expected

FDA's Push for Expanded Authority

Current Limitations of Section 506J

Section 506J, as currently written, limits mandatory reporting requirements to periods during or in advance of a public health emergency. This is a significant constraint. Outside of declared emergencies, the FDA can only encourage -- not require -- manufacturers to report supply chain disruptions. The agency must rely on voluntary notifications, which are inconsistent and often delayed.

This limitation became acutely apparent as the formal COVID-19 public health emergency declaration ended. Many of the supply chain vulnerabilities exposed during the pandemic persisted well beyond the emergency declaration, yet the FDA's authority to mandate reporting reverted to the narrower pre-emergency baseline.

FDA's Legislative Priorities

In testimony before Congress, the FDA's Director of the Center for Devices and Radiological Health, Dr. Michelle Tarver, has articulated the agency's case for expanding Section 506J authority. The key elements of the FDA's advocacy include:

Expanding mandatory reporting beyond emergencies. The FDA is seeking legislative changes that would require manufacturers to report permanent discontinuances and manufacturing interruptions regardless of whether a public health emergency has been declared. The rationale is straightforward: supply chain disruptions do not wait for formal emergency declarations, and the agency needs consistent, year-round visibility into device availability.

Additional funding for CDRH Supply Chain Program. The FDA has requested increased Congressional appropriations to support the CDRH supply chain program, including staffing for OSCR, technology investments for supply chain surveillance and data analytics, and resources for international coordination with regulatory counterparts.

Broader device coverage. The FDA has indicated that the current 506J Device List may not capture all device categories where shortage reporting would be beneficial, and has expressed interest in expanding the list's scope.

The EU Comparison

The FDA's advocacy for expanded authority is informed by developments in the European Union. The EU has implemented a new device shortage notification requirement, effective January 10, 2025, that requires manufacturers to notify competent authorities of anticipated or actual supply chain disruptions -- without limiting this obligation to emergency periods. This gives EU hospitals and healthcare systems more proactive information about device availability than their US counterparts currently have.

The contrast is notable. As of 2025, European regulators receive manufacturer notifications about device shortages on an ongoing basis, while the FDA must largely rely on voluntary reporting outside of declared emergencies -- unless Congress acts to expand Section 506J authority.

Mandatory vs. Voluntary Reporting: A Practical Framework

Understanding when reporting is mandatory versus voluntary is essential for compliance. The following framework summarizes the key distinctions:

Best Practice: Treat All Reporting as Mandatory

The most effective approach for manufacturers is to treat voluntary and mandatory reporting identically. Build a single internal process that captures all supply chain disruptions and routes them to the FDA through the appropriate channel, regardless of whether the device is on the 506J Device List or whether a public health emergency has been declared.

This approach has several advantages:

• It eliminates the compliance risk of misclassifying a device or misjudging whether an emergency declaration applies
• It builds organizational muscle for shortage reporting that will be immediately applicable if Section 506J is expanded to cover non-emergency periods
• It positions the company as a responsible supply chain partner in the eyes of the FDA, which can be valuable during inspections, pre-submission meetings, and regulatory interactions
• It supports patient safety by ensuring the FDA has the information it needs to coordinate mitigations

Actionable Steps for Manufacturers

1. Know Your 506J Status

Identify which of your devices appear on the 506J Device List. Cross-reference your entire product portfolio against the current list and flag any matches in your regulatory database. Subscribe to FDA updates so you are notified when product codes are added or removed.

2. Establish an Internal Shortage Reporting Process

Create a documented, trained, and tested internal process for identifying and reporting supply chain disruptions. This process should:

• Define what constitutes a "permanent discontinuance" and a "manufacturing interruption" in your specific context
• Establish criteria for assessing whether a disruption is likely to lead to a "meaningful disruption in supply"
• Assign clear roles and responsibilities for notification decisions (typically involving regulatory affairs, supply chain, and senior management)
• Include escalation paths for situations where the reporting decision is ambiguous
• Be integrated with your quality management system, including complaint handling, corrective and preventive action (CAPA), and management review

3. Register for the 506J Notification Portal

Ensure that your regulatory affairs team has active accounts on the FDA's 506J notification portal at fdaprod.secure.force.com/shortages/. Do not wait until a disruption occurs to set up access. Test the portal periodically and keep contact information current.

4. Monitor Your Supply Chain Proactively

Section 506J reporting requires you to assess whether a disruption is likely to cause a meaningful supply impact. This assessment is only credible if you have visibility into your supply chain. Invest in:

• Tier 2 and Tier 3 supplier mapping -- understanding who supplies your suppliers and where single points of failure exist
• Inventory monitoring and demand forecasting -- maintaining accurate data on your own inventory levels, customer demand patterns, and safety stock positions
• Supplier risk assessment -- regularly evaluating your suppliers' financial stability, geographic concentration, regulatory compliance, and operational resilience
• Component-level shortage tracking -- monitoring industry-wide shortage reports, trade publications, and FDA communications for early warning signals

5. Prepare for Regulatory Expansion

The FDA's push to expand Section 506J authority beyond public health emergencies has bipartisan Congressional interest and alignment with international trends (particularly the EU's new requirement). Manufacturers should prepare for this expansion by:

• Treating voluntary reporting as standard practice now, rather than waiting for a legal mandate
• Including shortage reporting readiness in internal audits and management reviews
• Engaging with industry associations (AdvaMed, MDMA, MITA) that are tracking legislative developments
• Building IT systems and processes that can scale from voluntary to mandatory reporting without requiring a complete redesign

6. Develop Shortage Mitigation Plans

For each device on the 506J Device List -- and ideally for all devices with significant market share or critical clinical applications -- develop a shortage mitigation plan that includes:

• Alternative suppliers or manufacturing sites that could be activated if a disruption occurs
• Inventory buffers appropriate to the device's clinical criticality and supply chain risk profile
• Customer communication templates that can be deployed quickly if a shortage develops
• Regulatory pathway assessments for any product or manufacturing changes needed to activate alternative supply sources

7. Monitor the Discontinuance List

Regularly review the FDA's Discontinuance List for devices in your portfolio or in your supply chain. If a component, raw material, or sub-assembly that you depend on appears on the list, initiate a supply chain risk assessment and alternative sourcing evaluation immediately. The discontinuance of a single upstream component can cascade through multiple finished device manufacturers simultaneously.

8. Engage with OSCR Proactively

OSCR is not solely an enforcement office. It is a coordination office that works with manufacturers to prevent and resolve shortages. If you anticipate a supply chain disruption, engaging with OSCR early -- through the notification portal or direct communication -- can facilitate the agency's ability to support mitigation efforts, including temporary regulatory flexibilities, communication with the healthcare community, and coordination with other manufacturers.

Looking Ahead

The medical device shortage reporting landscape is evolving. Section 506J established the foundational legal framework, but its current limitation to public health emergencies leaves a significant gap in the FDA's visibility into device supply chains. The EU's new requirement, effective January 2026, creates a contrasting model where year-round mandatory reporting gives regulators continuous supply chain intelligence. FDA's leadership has made clear that it views expanded authority as essential to fulfilling the agency's public health mission.

For manufacturers, the trajectory is unambiguous: shortage reporting requirements will likely expand in scope, apply more broadly across device categories, and become a year-round obligation rather than an emergency-triggered one. Companies that invest in robust shortage reporting processes, proactive supply chain monitoring, and strong relationships with OSCR today will be better positioned to comply with future requirements and, more importantly, to protect the patients who depend on their devices.